NOTV

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 2004 for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc., or BASi). The company provides laboratory services and manufactures scientific instruments for pharmaceutical development, medical research, and academic institutions. The company operates in two segments: Research Services and Research Products.

Key Financial Metrics

Cash Flow: Net cash used by operating activities was $594,000. Net cash used by investing activities was $532,000. Net cash provided by financing activities was $1,500,000.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 10.5% ($917,000) year-over-year. Service revenue grew significantly ($7,290,000 vs. $5,978,000), driven by new contracts in West Lafayette, IN, and facility balancing in McMinnville, OR. Product revenue declined 14% ($2,404,000 vs. $2,799,000) due to an unusually large order in the prior year that did not repeat.
• Profitability Turnaround: The company moved from an operating loss of $84,000 to an operating income of $905,000. Net income improved from a loss of $130,000 to income of $404,000.
• Margin Expansion: Gross margin improved to 37.4% from 30.0%, primarily due to higher service revenue spreading fixed costs over a larger base and improved utilization of laboratory capacity.
• Expense Trends: Interest expense increased 33% to $275,000 due to higher average borrowings, the expensing of interest on completed construction projects, and rising interest rates. General and administrative expenses rose 4% due to annual pay increases and Sarbanes-Oxley compliance costs.

Outlook, Risks, and Unusual Items

• Subsequent Event (Sale-Leaseback): On January 5, 2005, the company sold its Baltimore clinical research building for $6,500,000 and leased back approximately 85% of the space. Proceeds were used to pay off the revolving credit facility and fund working capital. This transaction requires a letter of credit that reduces available borrowing capacity under the credit facility.
• Liquidity: As of December 31, 2004, the company had $1,394,000 in cash and approximately $1,200,000 in available borrowings. Management expects capital additions of $2,000,000 to $2,500,000 for the fiscal year.
• Internal Controls: Management disclosed that disclosure controls and procedures were not effective as of December 31, 2004, due to decentralized and obsolete accounting systems. The company is in the process of standardizing and updating these systems.
• Market Risks: The business is dependent on pharmaceutical industry R&D spending. Risks include patent expirations of major drugs, government regulation, and the impact of the Vioxx recall on clinical trial transparency requirements.

Investor Verification Checklist

• Internal Control Remediation: Verify the timeline and progress of the new accounting system implementation to ensure future reporting reliability.
• Debt Covenants: Confirm compliance with debt covenants regarding interest-bearing indebtedness to EBITDA ratios, especially given the recent sale-leaseback transaction and letter of credit requirements.
• Revenue Sustainability: Assess whether the service revenue growth is sustainable or dependent on specific delayed contracts that may not recur.
• Product Mix: Monitor product revenue trends to ensure the decline in the Culex product line does not indicate a broader market shift.
• Interest Rate Exposure: Review the impact of the fixed-rate mortgage decision versus variable-rate revolving credit exposure.